TAVI: New trials and registries offer further welcome evidence – U.S. CoreValve, CHOICE, and GARY

Authors

  • Michele Pighi NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom
  • Roberta Serdoz NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom
  • Ismail Dogu Kilic NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom
  • Sara Abou Sherif NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom
  • Alistair Lindsay NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom
  • Carlo Di Mario NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom

Abstract

The introduction of transcatheter aortic valve implantation (TAVI) has resulted in a paradigm shift in the treatment of patients with severe aortic stenosis. Data from the recent U.S CoreValve Trial suggest, for the first time, that TAVI is associated with a significantly higher rate of survival at one year compared to surgical aortic valve replacement (SAVR) in the treatment of high-risk patients affected by severe aortic stenosis. The present review discusses this study and the current evidence about TAVI, for the treatment of severe aortic stenosis, from major trials and real world registries. 

Downloads

Published

2017-06-02

Issue

Vol. 2014 No. 1 (2014)

Section

Lessons from the trials

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.